News tagged with bevacizumab
Related topics: patients , breast cancer , lung cancer , chemotherapy , ovarian cancer
Chemo combo promising for pancreatic neuroendocrine tumors
(HealthDay) -- The combination of temozolomide and bevacizumab seems to benefit patients with advanced pancreatic neuroendocrine tumors (NETs), according to a study published online July 9 in the Journal of ...
Cancer
Jul 13, 2012 |
not rated yet |
0
Study to test success of vision loss drug which could slash treatment costs for NHS
Nottingham researchers are leading a study to test the effectiveness of a controversial drug in the treatment of a common loss of vision.
Ophthalmology
Jul 11, 2012 |
5 / 5 (1) |
0
Metastatic breast cancer: Bevacizumab slows progression, but has no impact on survival
The cancer drug bevacizumab (Avastin) offers only a modest benefit in delaying disease progression in patients with advanced stage breast cancer, according to a systematic review by Cochrane researchers. The researchers assessed ...
Cancer
Jul 10, 2012 |
not rated yet |
0
Better treatment for brain cancer revealed by new molecular insights
Nearly a third of adults with the most common type of brain cancer develop recurrent, invasive tumors after being treated with a drug called bevacizumab. The molecular underpinnings behind these detrimental effects have now ...
Cancer
Jul 09, 2012 |
not rated yet |
0
|
Adding erlotinib to bevacizumab/chemoradiotherapy regimen for pancreatic cancer safe, tolerable
The addition of high doses of erlotinib to the treatment regimen of bevacizumab and capecitabine with radiotherapy seems to benefit patients with locally advanced pancreatic cancer, according to results of a phase I study ...
Cancer
Jun 19, 2012 |
not rated yet |
0
ASCO: Continuing avastin with 2nd-line chemo ups survival
(HealthDay) -- Continuing use of bevacizumab (Avastin) in combination with second-line chemotherapy improves overall survival (OS) and progression-free survival (PFS) in patients with metastatic colorectal ...
Cancer
Jun 05, 2012 |
not rated yet |
0
Drug cocktail boosts ovarian cancer survival time
A drug cocktail that combines chemotherapy with Avastin was shown to double the amount of time patients lived without progression of ovarian cancer, according to research released Saturday.
Cancer
Jun 02, 2012 |
not rated yet |
0
Liver metastases and its prognostic significance in men with metastatic prostate cancer
Liver metastases predicts shorter overall survival in men with metastatic castration-refractory prostate cancer (mCRPC), according to data being presented at the 2012 American Society of Clinical Oncology Annual Meeting in ...
Cancer
May 31, 2012 |
not rated yet |
0
Biomarker predicts response to cancer treatment
VIB researcher Diether Lambrechts, associated with KU Leuven, has discovered a biomarker that might potentially predict which patients will benefit more from treatment with bevacizumab (Avastin). If validated, this discovery ...
Cancer
May 21, 2012 |
not rated yet |
0
Avastin and Lucentis are equivalent in treating age-related macular degeneration
At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although ...
Ophthalmology
Apr 30, 2012 |
not rated yet |
1
Avastin no benefit to older lung cancer patients: study
(HealthDay) -- Medicare patients who have advanced non-small cell lung cancer appear to get no survival benefit from adding the drug Avastin to standard chemotherapy, researchers from the Dana-Farber Cancer ...
Cancer
Apr 17, 2012 |
not rated yet |
0
|
Study examines drug regimen for the treatment of non-small cell lung cancer among older patients
Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients ...
Cancer
Apr 17, 2012 |
not rated yet |
0
Study reports two-year outcomes of diabetic macular edema treatment
A randomized controlled trial involving patients with persistent clinically significant diabetic macular edema (swelling of the retina) suggests the greater efficacy of bevacizumab compared with macular laser therapy that ...
Ophthalmology
Apr 09, 2012 |
not rated yet |
0
Drug combination may provide option to patients with NSCLC ineligible for bevacizumab
A combination of nab-paclitaxel and carboplatin for the treatment of non-small cell lung cancer may be a promising option for patients ineligible for treatment with bevacizumab, according to data presented at the AACR Annual ...
Cancer
Apr 03, 2012 |
not rated yet |
0
Diabetes treatment doubles skin cancer drug's effectiveness
Combining the experimental drug Avastin (bevacizumab) with the diabetes drug Metformin almost doubles its ability to reduce skin cancer growth, according to a study in Cancer Discovery.
Cancer
Apr 02, 2012 |
not rated yet |
0
